The possibility of using magnetic nanoparticles to increase the therapeutic efficiency of Herceptin antibody

References

[1] Buzug TM. Magnetic particle imaging – from particle science to imaging technology. Biomed Eng 2013; 58: 489–491.10.1515/bmt-2013-0117Search in Google Scholar PubMed

[2] Chapman S, Dobrovolskaia M, Farahani K, et al. Nanoparticles for cancer imaging: the good, the bad, and the promise. Nano Today 2013; 8: 454–460.10.1016/j.nantod.2013.06.001Search in Google Scholar PubMed PubMed Central

[3] Chen J, Zhu S, Tong L, et al. Superparamagnetic iron oxide nanoparticles mediated ¹³¹I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice. BMC Cancer 2014; 14: 114–121.10.1186/1471-2407-14-114Search in Google Scholar PubMed PubMed Central

[4] Chomoucka J, Drbohlavova J, Huska D, Adam V, Kizek R, Hubalek J. Magnetic nanoparticles and targeted drug delivering. Pharmacol Res 2010; 62: 144–149.10.1016/j.phrs.2010.01.014Search in Google Scholar PubMed

[5] Davoli A, Hocevar BA, Brown TL. Progression and treatment of HER2-positive breast cancer. Cancer Chemother Pharmacol 2010; 65: 611–623.10.1007/s00280-009-1208-1Search in Google Scholar PubMed

[6] DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res 2008; 68: 8643–8653.10.1158/0008-5472.CAN-07-6611Search in Google Scholar PubMed

[7] Finas D, Baumann K, Sydow L, et al. Detection and distribution of superparamagnetic nanoparticles in lymphatic tissue in a breast cancer model for magnetic particle imaging. Biomed Eng 2012; 57: 81–83.10.1515/bmt-2012-4158Search in Google Scholar

[8] Fleck L. The costs of caring: Who pays? Who profits? Who panders? Hastings Cent Rep 2006; 36: 13–17.10.1353/hcr.2006.0040Search in Google Scholar PubMed

[9] Frese J, Hrdlicka L, Mertens M, et al. Non-invasive imaging of tissue-engineered vascular endothelium with iron oxide nanoparticles. Biomed Eng 2012; 57: 1065–1067.10.1515/bmt-2012-4472Search in Google Scholar

[10] Funovicsa MA, Kapellerb B, Hoellerc C, et al. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging 2004; 22: 843–850.10.1016/j.mri.2004.01.050Search in Google Scholar PubMed

[11] Jia Y, Yuan M, Yuan H, et al. Co-encapsulation of magnetic Fe₃O₄ nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery. Int J Nanomed 2012; 7: 1697–1708.Search in Google Scholar

[12] Knezevic NZ, Durand JO. Large pore mesoporous silica nanomaterials for application in delivery of biomolecules. Nanoscale 2015; 7: 2199–2209.10.1039/C4NR06114DSearch in Google Scholar

[13] Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72: 77–89.10.1016/0022-1759(84)90435-6Search in Google Scholar

[14] Lowry OH, Rosebrough NJ, Farr L, Randal RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–269.10.1016/S0021-9258(19)52451-6Search in Google Scholar

[15] Ludwig F, Eberbeck D, Lowa N, et al. Characterization of magnetic nanoparticle systems with respect to their magnetic particle imaging performance. Biomed Eng 2013; 58: 535–545.10.1515/bmt-2013-0013Search in Google Scholar PubMed

[16] Malhotra V, Perry MC. Classical chemotherapy: mechanisms, toxicities and the therapeutic window. Cancer Biol Ther 2003; 2: 2–4.10.4161/cbt.199Search in Google Scholar

[17] Murthy RK, Varma A, Mishra P, et al. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 2014; 120: 1932–1938.10.1002/cncr.28689Search in Google Scholar PubMed

[18] Oberle A, Ludtke-Buzug K. Stability analysis of superparamagnetic iron oxide nanoparticles (Spions) at 37°C. Biomed Eng 2013; 58: 4099–4100.10.1515/bmt-2013-4099Search in Google Scholar PubMed

[19] Rasaneh S, Rajabi H, Babaei MH, Akhlaghpoor S. MRI contrast agent for molecular imaging of the HER2/neu receptor using targeted magnetic nanoparticles. J Nanopart Res 2011; 13: 2285–2293.10.1007/s11051-010-9991-5Search in Google Scholar

[20] Ulas A1, Kos T, Avci N, et al. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival. Asian Pac J Cancer Prev 2015; 16: 1643–1649.10.7314/APJCP.2015.16.4.1643Search in Google Scholar

[21] Xu JK, Zhang FF, Sun JJ, Sheng J, Wang F, Sun M. Bio and nanomaterials based on Fe₃O₄. Molecules 2014; 19: 506–528.Search in Google Scholar

[22] Yu AF, Yadav NU, Lung BY, et al. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat 2015; 149: 489–495.10.1007/s10549-014-3253-7Search in Google Scholar PubMed PubMed Central

[23] Zeinali Sehrig F, Majidi S, Nikzamir N, Nikzamir N, Nikzamir M, Akbarzadeh A. Magnetic nanoparticles as potential candidates for biomedical and biological applications. Artif Cells Nanomed Biotechnol 2015; 23: 1–10.10.3109/21691401.2014.998832Search in Google Scholar PubMed